1Cannon CP,Weintraub WS,Demopoulos LA et al.Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein Ⅱb/Ⅲa inhibitor tirofiban.N Engl J Med,2001,344(25):1879.
2Wallentin L,Lagerqvist B,Husted S et al.Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary artery disease:the FRISC Ⅱ invasive randomised trial.FRISC Ⅱ Investigators.Fast Revascularisation during Instability in Coronary artery disease.Lancet,2000,356(9223):9.
3Fox KA,Poole-Wilson PA,Henderson RA et al.Interventional versus conservative treatment for patients with unstable angina or non ST elevation myocardial infarction:the British Heart Foundation RITA 3 randomised trial.Randomized Intervention Trial of unstable Angina.Lancet,2002,360(9935):743.
4Keeley EC,Boura JA,Grines CL.Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction:a quantitative review of 23 randomised trials.Lancet,2003,361(9351):13.
5Thune JJ,Hoefsten DE,Lindholm MG et al.Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty.Circulation,2005,112 (13):2017.
6Prasad A,Lennon RJ,Rihal CS et al.Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization.Am Heart J,2004,147(6):1066.
7Sousa JE,Costa MA,Abizaid AC et al.Sustained suppression of neointimal proliferation by sirolimus-eluting stents:one-year angiographic and intravas cular ultrasound follow up.Circulation,2001,104(17):2007.
8Regar E,Serruys PW,Bode C et al.Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL):sirolimus-eluting stents inhibit restenosis irrespective of the vessel size.Circulation,2002,106(15):1949.
9Schofer J,Schluter M,Gershlick AH et al.Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries:doubleblind,randomised controlled trial (E-SIRIUS).Lancet,2003,362(9390):1093.
10Grube E,Silber S,Hauptmann KE etal.TAXUS Ⅰ:six-and twelve-month results from a randomized,double-blind trial on a slow-release paclitaxel-elu ting stent for de novo coronary lesions.Circulation,2003,107(1):38.
2Rodkey SM, Ratliff NB, Young JB. Cardiomyopathy and myocardial failure. In: Topol EJ, ed. Coprehensive cardiovarscular medicine. Philadelphia: Lippincott-Raven Publishers,1998.2599-2601.
3Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices:summary article. Circulation,2002,15:2145-2161.
4Smith SC Jr, Dove JT, Jacobs AK, et al.ACC/AHA guidelines of percutaneous coronary interventions revision of the 1993 PTCA guidelines: a report of the American college of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). Circulation,2001,103:3019-3041.
5Senior R, Kaul S, Lahiri A. Myocardial viability predicts regression of remodeling following revascularisation compared to medical therapy in ischemic cardiomypathy. Eur Heart J,2000,Suppl:21.
6Abraham WT. Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure:the Multicenter Insync Randomized Clinical Evaluation(MIRACLE). J Card Fail,2000, 6:369-380.
7Lau CP, Yu CM, Chau E, et al. Reversal of left ventricular remodeling by synchronous biventricular pacing in heart failure. PACE,2000,23:1722-1725.
8Nelson GS, Berger RD, Fetics BJ, et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-brunch block .Circulation,2000,102:3053-3059.
9Yu CM, Chau E, Sanderson JE. Tissue doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation,2002,109:438-445.
10Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002, 288: 2411-2420.
2Rosuvastatin Registration Clinical Trial Group.Cardiovascular Institute and Fu Wai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China.瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究[J].中华心血管病杂志,2007,35(3):207-211. 被引量：117
4Han Y, Zhu Gj Han Lj et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease[J]. J Am Coil Cardiol, 2014, 63(1): 62-70.
5Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology[J]. Eur Heart J, 2005, 26(8): 804-847.
6Miller PS, Smith DG, Jones P. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterolgoals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of theSTELLAR Trial) [J]. Am J Cardiol, 2005, 95 ( 11 ) : 1314-1319.
7Larbi A, Khalil A, Douziech N, et al. Oxidized low-density lipoproteins induced inflammatory process during atherogenesis with aging[J]. Radiat Phys Chem, 2005, 72(2-3): 387-397.
8Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type Ⅱ a or Ⅱb hypercholesterolemia[J]. Am J Cardiol, 2002, 89(3): 268-275.
9Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials [J] ? Am J Cardiol, 2006, 98 (11A): 18P-25P.
10Probstfield JL, Rifkind BM. The Lipid Research Clinics Coronary Primary Prevention Trial: design, results, and implications[J]. Eur J Clin Pharmacol, 1991, 40(Suppl 1): S69-S75.
